Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials

Abstract Background Relebactam is a new inhibitor of class A and class C β-lactamases. The FDA has approved combining IMI/CS/REL to treat some infectious diseases. This study systematically reviews the efficacy and safety of IMI/CS/REL based on existing clinical trials so as to provide a reference f...

Full description

Bibliographic Details

Published in:	BMC Infectious Diseases
Main Authors:	Wenjuan Lei, Yan Duan, Mingyan Xin, Min Tian, Jia Xu
Format:	Article
Language:	English
Published:	BMC 2025-09-01
Subjects:	Imipenem/cilastatin/relebactam Efficacy Safety Carbapenem resistant gram-negative bacteria
Online Access:	https://doi.org/10.1186/s12879-025-11499-w